Premium
Application of affinity aqueous two‐phase systems for the fractionation of CD133 + stem cells from human umbilical cord blood
Author(s) -
GonzálezGonzález Mirna,
RitoPalomares Marco
Publication year - 2015
Publication title -
journal of molecular recognition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.401
H-Index - 79
eISSN - 1099-1352
pISSN - 0952-3499
DOI - 10.1002/jmr.2374
Subject(s) - peg ratio , stem cell , polyethylene glycol , ficoll , bioprocess , chemistry , chromatography , umbilical cord , antibody , biology , biochemistry , immunology , peripheral blood mononuclear cell , microbiology and biotechnology , in vitro , paleontology , finance , economics
In a further attempt to establish a novel stem cell primary recovery strategy, the use of aqueous two‐phase systems (ATPS) complemented with the use of antibodies (known as immunoaffinity ATPS) is explored in this work. This type of liquid–liquid extraction systems exploits antigen–antibody affinity and represents a novel and selective approach for the purification of stem cells. The proposed bioengineering strategies include the implementation of traditional [polyethylene glycol (PEG), dextran (DEX) and ficoll] and novel (Ucon) immunoaffinity ATPS to prove the viability of cluster of differentiation 133 (CD133 + ) stem cells from human umbilical cord blood. Furthermore, the addition of the antibody is implemented to identify conditions under which contaminants and stem cells of interest concentrate in opposite phases. The objective of this work is to establish the initial basis for the development of a novel and scalable purification bioprocess for the selective recovery of CD133 + stem cells employing immunoaffinity ATPS. The reported methodology allows a partitioning of 62% CD133 + stem cells to the top phase of the ficoll 400,000–DEX 70,000 immunoaffinity ATPS. In PEG 8,000–DEX 500,000 and Ucon–DEX 75,000 systems, no difference was observed when compared with the conventional ATPS (without antibody addition), as the CD133 antibody does not have preference for the desired clean top phase. In all experiments, cell viability was at least 98% after ATPS recovery. This research highlights the challenges that must be addressed to allow the potential establishment of a separation process using immunoaffinity ATPS for the recovery and purification of stem cells. Copyright © 2015 John Wiley & Sons, Ltd.